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Methods: We studied adherence rates and predictors in the Finnish Geriatric Intervevntion Study to
Prevent Cognitive Impairment and Disability and Multidomain Alzheimer Preventive Trial preven-
tion trials, for all intervention components (separately and simultaneously). Finnish Geriatric Inter-
vevntion Study to Prevent Cognitive Impairment and Disability participants received a 2-year
multidomain lifestyle intervention (physical training, cognitive training, nutritional counseling,
and cardiovascular monitoring). Multidomain Alzheimer Preventive Trial participants received a
3-year multidomain lifestyle intervention (cognitive training, physical activity counseling, and nutri-
tional counseling) with either an omega-3 supplement or placebo.
Results: Adherence decreased with increasing intervention complexity and intensity: it was highest
for cardiovascular monitoring, nutritional counseling, and the omega-3 supplement, and lowest for
unsupervised computer-based cognitive training. The most consistent baseline predictors of adher-
ence were smoking and depressive symptoms.
Discussion: Reducing participant burden, while ensuring that technological tools are suitable for
older individuals, maintaining face-to-face contacts, and taking into account participant characteris-
tics may increase adherence in future trials.
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Modifiable risk factors may account for 35% of dementia
cases [1]. A reduction of 10% per decade in the prevalence of
several lifestyle risk factors, including obesity, physical
inactivity, diabetes, hypertension, and smoking, could
potentially reduce the number of worldwide cases ofghts reserved.
N. Coley et al. / Alzheimer’s & Dementia 15 (2019) 729-741730Alzheimer’s disease dementia, the most common form of de-
mentia, in 2050 by around 9 million [2]. However, this pro-
jection assumes, in addition to a causal relationship, that
implementing lifestyle changes would be acceptable to large
numbers of people for long periods of time [3].
Because of the multifactorial nature of dementia, in the
past decade, there has been growing interest in multidomain
interventions for dementia prevention [3]. These interven-
tions target multiple risk factors simultaneously and are ex-
pected to generate additive or synergistic preventive effects,
compared with interventions targeting one risk factor alone.
The first large-scale randomized controlled trials (RCTs)
of multidomain interventions have been completed in the
past few years and have shown mixed results: in the Finnish
Geriatric Intervention Study to Prevent Cognitive Impair-
ment and Disability (FINGER) trial, an intensive 2-year
multidomain intervention targeting diet, exercise, cognitive
training, and vascular risk monitoring improved cognition
compared with a health education control [4], whereas the
longer but less intensive Multidomain Alzheimer Preventive
Trial (MAPT) and Prevention of Dementia by Intensive
Vascular Care multidomain interventions yielded neutral re-
sults from the primary analyses, but suggested that specific
subgroups at increased risk of dementia may benefit from
such interventions [5,6].
One factor that may influence intervention efficacy is
adherence. Health behaviors are notoriously difficult to
change, and long-term adherence to lifestyle recommenda-
tions is often lower than adherence to medication [7].
Furthermore, intervention periods in dementia prevention
trials are typically relatively long (2–7 years, for example),
which may further reduce adherence. Adherence may also
be affected by the nature, intensity, and method of delivery
of interventions, as well as by participant characteristics.
However, there are a few data available about adherence to
multidomain interventions in older adults [8,9].
The aim of this analysis was to describe and compare
adherence to multidomain interventions for the prevention
of cognitive decline in two large-scale trials, and within
each trial, to identify predictors of adherence to individual
components of the intervention and to the multidomain inter-
ventions as a whole.2. Methods
2.1. Participants and interventions
We analyzed data from the FINGER and MAPT trials,
both of which have previously been described in detail
[4,5,10,11]. Briefly, FINGER was conducted in six Finnish
centers and included 1260 individuals aged 60 to 77 years
with a Cardiovascular Risk Factors, Aging, and Incidence
of Dementia dementia risk score [12] of 6 or more and cogni-
tive function at the mean level or slightly lower than ex-
pected for age, who were recruited from previous
population-based national surveys. Participants were ran-domized to an intensive multidomain intervention or a con-
trol group. MAPT was conducted in 13 French centers and
included 1680 subjects aged 70 years and older with a
Mini-Mental Status Examination (MMSE) [13] score of 24
or more, and a subjective memory complaint, a limitation
in one instrumental activity of daily living [14], and/or
slow walking speed (0.8 m/s). MAPT participants were
mainly recruited from memory clinics, media campaigns,
and healthy aging conferences (conducted in collaboration
with pension organizations) [15], and were randomized to
one of the following four groups: (1) multidomain lifestyle
intervention 1 omega-3 supplement; (2) multidomain life-
style intervention 1 placebo; (3) omega-3 supplement
alone; and (4) placebo alone. For the present analysis, we
included only subjects assigned to receive a multidomain
intervention (with omega-3 supplement or placebo for
MAPT subjects).
The interventions tested in each trial are summarized in
Fig. 1 and have been described in detail elsewhere [5,10].
The FINGER intervention lasted for 2 years and included
computer-based cognitive training, gym-based physical ex-
ercise training, nutritional advice, and cardiovascular consul-
tations. Each component of the intervention was delivered
separately in group and/or individual sessions or independent
training. In MAPT, the multidomain lifestyle intervention
lasted for 3 years and involved pencil- and paper-based
cognitive training, advice and education about physical ac-
tivity (including the development of an individualized
home-based exercise program), and nutritional advice. It
was delivered in group and individual sessions, which simul-
taneously covered all three components. Furthermore, there
were three annual preventive consultations (although adher-
ence to this part of the intervention was not assessed in the
current analysis because of the limited number of sessions).
All MAPT participants were also asked to take two capsules
a day containing either a placebo or a total of 800 mg doco-
sahexaenoic acid and 225 mg eicosapentaenoic acid (pla-
cebo/omega-3 assignment was double-blind). Both trials
were registered at ClinicalTrials.gov (FINGER,
NCT01041989; MAPT, NCT00672685) and were approved
by the relevant local ethical committees. Written informed
consent was obtained from all participants.2.2. Outcomes
Adherence indicators are described in Fig. 1, and were
based on attendance at group or individual sessions, comple-
tion of cognitive training tasks, and pill counts. For this anal-
ysis, participants were considered adherent if they
completed at least 66% of the prescribed interventions. We
used the same definition for both trials to enable a compari-
son of results. Although, there is no consensus about the
optimal level of participation in lifestyle interventions, this
adherence definition was chosen because of its relatively
widespread use in the literature, and because it has been sug-
gested to be particularly suitable for behavioral interventions
Fig. 1. Description of intervention components and adherence indicators in theMAPTand FINGER trials. The preventive consultations were not included in the
multidomain adherence indicator in MAPT. Abbreviations: FINGER, Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability;
MAPT, Multidomain Alzheimer Preventive Trial.
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predefined cutoffs used in each individual trial’s primary
analysis (50% for FINGER and 75% for MAPT).
Adherence rates were calculated for the entire follow-up
period, except for participants who died or dropped out
because of medical reasons, for whom the adherence rate
was calculated only until the time of dropout. All sessions
were given equal weighting in the adherence indicators,
regardless of their timing or whether they were group or in-
dividual sessions. This approach enabled us to study the
extent to which participants adhered to the interventions
that they were assigned, as a whole.2.3. Predictor variables
Candidate baseline predictor variables were selected
based on a literature review of factors associated with adher-
ence and known dementia risk factors. The following core
set of variables was assessed in both studies: sociodemo-
graphics (age, sex, and education), cognitive function
(MMSE [13] and Trail Making Test [17], subjective memory
performance), depressive symptoms (Zung depression scale
[18] score 45 (FINGER) or Geriatric Depression Scale
[19] score.5 (MAPT)), physical performance (Short Phys-ical Performance Battery [20]), self-reported physical activ-
ity (total minutes of exercise per week calculated using the
short (MAPT) or modified (FINGER) version of the Minne-
sota Leisure Time Physical Activity Questionnaire [21,22]),
cardiovascular disease, and risk factors (self-reported
history of diabetes, stroke, myocardial infarction, heart
disease, high blood pressure, and high cholesterol; body
mass index; smoking status; alcohol consumption).
In addition, the following predictors were assessed in
FINGER only: marital status, income, family history of de-
mentia, employment, participants’ initial perception of the
study (used as a proxy for self-efficacy), dietary habits (modi-
fied recommended Finnish diet score) [23], and previous
experience with computers. Several of these variables were
also assessed in MAPT as part of a substudy [24] and were
used to characterize the population at baseline but not as pre-
dictor variables, as they were only available for a subset.
Apolipoprotein E (APOE) genotype was also assessed as a
predictor in both studies in additional sensitivity analyses.2.4. Statistical analyses
All analyses were conducted in parallel in the two trials.
Baseline characteristics were described using means
Table 1
Baseline characteristics of FINGER and MAPT participants
Characteristics FINGER (N 5 631) MAPT (N 5 837) P*
Age (y), mean (SD) 69.0 (4.7) 75.3 (4.3) ,.001
Male, N (%) 345 (54.7) 298 (35.6) ,.001
Education,y N (%) ,.001
Low 260 (41.5) 175 (21.1)
Intermediate 208 (33.2) 290 (35.0)
High 158 (25.2) 364 (43.9)
MMSE (score/30), mean (SD) 26.7 (2.0) 28.1 (1.6) ,.001
TMT-A (completion time, s), mean (SD) 57.9 (19.9) 46.9 (17.2) ,.001
SPPB ,10, N (%) 75 (12.4) 184 (22.1) ,.001
Alcohol intake within European recommended limit,z N (%) 579 (92.3) 632 (83.6) ,.001
Smoking status, N (%) ,.001
Never 356 (57.1) 399 (55.0)
Former 207 (33.2) 299 (41.2)
Current 60 (9.6) 27 (3.7)
BMI, mean (SD) 28.3 (4.5) 26.1 (4.1) ,.001
SBP, mean (SD) 140.2 (16.6) 141.8 (19.6) .098
DBP, mean (SD) 80.5 (9.7) 78.9 (11.6) .006
Medical history, N (%)
Diabetes 85 (13.6) 54 (7.1) ,.001
High BP 424 (67.4) 379 (50.0) ,.001
High cholesterol 410 (65.4) 336 (44.3) ,.001
Stroke 33 (5.3) 33 (4.4) .435
MI 33 (5.3) 23 (3.0) .038
Medication use, N (%)
Antihypertensives 327 (52.4) 363 (48.0) .100
Antidiabetics 80 (12.8) 49 (6.5) ,.001
Statins 256 (42.2) 259 (34.2) .002
Single,x N (%) 172 (27.3) 267 (42.5) ,.001
Family history of dementia,x,{ N(%) 152 (25.9) 158 (28.4) .346
Good self-rated memory,#N (%) 279 (44.4) 197 (23.5) ,.001
Depressive symptoms,**N (%) 61 (10.1) 148 (17.8) ,.001
100 min physical activity/wk,yyN (%) 390 (71.0) 675 (81.4) ,.001
Low income,x,zzN (%) 147 (24.2) 33 (5.7) ,.001
Previous computer use, N (%) 336 (54.0) N/A N/A
Nonpositive perception of study, N (%) 43 (6.8) N/A N/A
Low diet scorexx 248 (39.6) N/A N/A
Abbreviations: BMI, Body mass index; BP, blood pressure; DBP, diastolic blood pressure; FINGER, Finnish Geriatric Intervention Study to Prevent Cogni-
tive Impairment and Disability; MAPT, Multidomain Alzheimer Preventive Trial; MI, myocardial infarction; MMSE, Mini-Mental Status Examination; SBP,
systolic blood pressure; SD, standard deviation; SPPB, Short Physical Performance Battery; TMT-A, Trail Making Test–part A.
P values ,.05 are highlighted in bold.
*Data shown in italic text indicate that the variable is not directly comparable between the two studies (i.e., the information was not collected in the sameway
or was only collected in one study).
yLow education 5 primary school certificate or lower; intermediate education 5 middle/vocational school; high education 5 high school diploma (e.g.,
baccalaureate) or higher.
zAlcohol intake 7 units/wk for women and 14 units/wk for men.
xVariables only collected for a subset of MAPT participants (N5 635) who participated in the "Representations and Practices of Prevention in Elderly Pop-
ulations: Investigating Acceptance to Participate in and Adhesion to an Intervention Study for the Prevention of Alzheimer’s disease" (ACCEPT) substudy.
{Direct family history, that is, one or both parents.
#FINGER: subjective memory rated above average; MAPT: visual analog scale rated ,40 (with 0 being perfect memory function and 100 being very bad
memory function).
**Zung depression score 45/80 for FINGER; Geriatric Depression Scale .5/15 for MAPT.
yyTotal minutes of self-reported exercise per week were calculated from the short (MAPT) or modified (FINGER) version of the Minnesota Leisure Time
Physical Activity Questionnaire.
zzHousehold income 20,000V per year for FINGER, ,1000V per month for MAPT.
xxModified Finnish Recommended Diet score (tertile 1 vs. other tertiles).
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between the two trials using t tests and rank sum tests for
quantitative variables and c2 tests for qualitative variables.
Predictors of adherence (defined as completing 66% of
interventions) were assessed in multilevel logistic regressionmodels containing a random intercept to take into account
within-center correlations. Identical multivariate models
were run for each adherence indicator, and included all vari-
ables that were significantly (P , .05) associated with at
least one adherence indicator in univariate analyses, or that
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the literature. The primary analyses included the core set
of predictor variables available in both trials. APOE geno-
type was tested as a predictor variable in sensitivity analyses
only, because of a high rate of missing data. The additional
FINGER predictor variables were included in secondary an-
alyses, and the alternative adherence definitions were used in
sensitivity analyses. No imputation of missing data was per-
formed; each model therefore included only subjects with no
missing data for the relevant outcome measure (adherence
indicator(s)) and independent variables.
Analyses were performed using Stata version 14.1 (Stata-
Corp LP, College Station, TX, USA).3. Results
3.1. Participants
Eight hundred thirty-seven MAPT subjects and 631
FINGER subjects were included in the analysis, of whom
77% and 86%, respectively, completed the full follow-up
period (3 years for MAPT and 2 years for FINGER). There
were significant differences between the two trials’ partici-
pants for nearly all the baseline characteristics assessed
(Table 1). Notably, MAPT participants were older, with
poorer physical performance, but a higher level of education,
and better objective cognitive performance. FINGER partic-
ipants had more cardiovascular risk factors and were more
predominantly male.
3.2. Adherence rates
In FINGER, adherence was highest for cardiovascular
monitoring (94.6% were adherent using the FINGER pre-
specified definition, and 92.9% were adherent using the
common 66% definition of adherence) and lowest for
cognitive training (47.2% and 24.7%, for each definition,
respectively), and 38.9% (19% using the common adher-
ence definition) of participants simultaneously adhered
to all four intervention components (Fig. 2). In MAPT,
adherence was higher for the omega-3/placebo capsules
(71.5% were adherent using the MAPT prespecified defi-
nition and 76.1% using the common 66% definition) than
for the multidomain sessions (53.5% and 64.4%), and
50.7% (61.1% with the common definition) of subjects
simultaneously adhered to both the supplement/placebo
and the multidomain sessions. In addition, 90.1%,
71.9%, and 62.3% of MAPT subjects attended the
baseline, 1- and 2-year cardiovascular consultations,
respectively.
3.3. Factors associated with adherence to individual
intervention components
No baseline factors were associated with adherence
to the FINGER cardiovascular consultations (Table 2;Supplementary Fig. 1). However, for the nutrition compo-
nent, current smoking (odds ratio [OR] 0.32 [95% confi-
dence interval [CI] 0.16–0.61], P 5 .001) was associated
with poorer adherence, and obesity (2.35 [1.28–4.30],
P 5 .006) and a history of stroke (5.22 [1.13–24.05],
P 5 .034) were associated with better adherence. For phys-
ical activity, older age (0.95 [0.91–0.99], P 5 .027), poorer
global cognitive function (0.66 [0.44–0.99], P 5 .046), cur-
rent smoking (0.47 [0.23–0.96], P 5 .038), and a history of
diabetes (0.49 [0.27–0.90], P 5 .022) were associated with
poorer adherence, whereas 100 minutes or more of self-
reported physical activity (1.90 [1.20–3.00], P 5 .006)
were associated with better adherence. For cognitive
training, older age (0.93 [0.89–0.98], P 5 .009) and current
smoking (0.24 [0.09–0.70], P 5 .008) were associated with
poorer adherence, and an intermediate level of education
(1.95 [1.18–3.23], P 5 .009) and 100 minutes or more of
self-reported physical activity (1.86 [1.08–3.21], P 5 .026)
were associated with better adherence.
In MAPT (Table 3; Supplementary Fig. 1), poorer global
cognitive function (0.64 [0.44–0.95], P 5 .024), depressive
symptoms (0.47 [0.30–0.72], P 5 .001), being overweight
(0.55 [0.37–0.83], P 5 .004), and a history of high blood
pressure (0.69 [0.48–1.00], P 5 .047) were associated with
poorer adherence to the multidomain intervention. Depres-
sive symptoms (0.43 [0.26–0.70], P5 .001) were also asso-
ciated with poorer adherence to omega-3/placebo, whereas
an intermediate level of education was associated with better
adherence to omega-3/placebo (2.04 [1.15–3.61], P5 .014).
In secondary FINGER analyses including additional pre-
dictor variables (Supplementary Table 1), marital status and
diet scores were not associated with adherence to any inter-
vention components, but low income was associated with
poorer adherence to the nutrition component (0.34 [0.19–
0.62], P , .001), and previous computer use (2.26 [1.30–
3.94], P 5 .004) and a nonpositive perception of the study
(0.19 [0.04–0.90], P 5 .036) were, respectively, associated
with better and poorer adherence to cognitive training.
Furthermore, in these fully adjusted models, age, education,
and cognitive function were no longer associated with adher-
ence to any intervention components, whereas other results
mostly remained stable.
In sensitivity analyses using each trial’s prespecified
definition of adherence (i.e., 50% for FINGER and
75% for MAPT), there were some differences in results,
notably in FINGER, with poorer executive function
becoming significantly associated with poorer adherence
to all intervention components except cardiovascular
monitoring (Supplementary Table 2). MAPT results re-
mained relatively stable, however (Supplementary
Table 3).
In a further sensitivity analysis, we also included APOE
genotype as a predictor variable, but there was no significant
association with adherence to any intervention components
in either trial (data not shown).
Fig. 2. Adherence rates in the FINGER and MAPT trials: proportion of subjects completing each trial’s predefined level of adherence (50% for FINGER,
75% for MAPT). Abbreviations: FINGER, Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability; MAPT, Multidomain Alz-
heimer Preventive Trial.
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intervention components
Older age (0.91 [0.86–0.97], P5 .002) and current smok-
ing (0.32 [0.11–0.95], P5 .039) were associated with poorer
simultaneous adherence to all FINGER intervention compo-
nents in the primary analysis, whereas an intermediate level
of education (2.05 [1.18–3.58], P 5 .011) was associated
with better simultaneous adherence (Table 4;
Supplementary Fig. 1). In the MAPT primary analysis,
depressive symptoms (0.47 [0.30–0.73], P 5 .001) and cur-
rent smoking (0.37 [0.15–0.94], P 5 .036) were associated
with poorer simultaneous adherence to both intervention
components (Table 4; Supplementary Fig. 1).
In sensitivity analyses using each study’s predefined
definition of simultaneous adherence (Supplementary
Tables 3 and 4), for FINGER, in addition to the associa-
tions observed in the main model, poorer executive func-
tion (1-second increase in Trail Making Test A score: 0.98
[0.97–1.00], P 5 .005) and physical performance (Short
Physical Performance Battery ,10: 0.24 [0.24–0.95],
P 5 .036) became associated with poorer adherence. Re-
sults were similar to the primary analysis for MAPT,
except that poorer global cognition (MMSE ,28) became
significantly associated with poorer adherence (0.64
[0.44–0.93], P 5 .019).
In a further sensitivity analysis, we also included
APOE genotype as a predictor variable, but there wasno significant association with simultaneous adherence
to all intervention components in either trial (data not
shown).
In a secondary FINGER analysis, including additional
predictor variables in the original model (Supplementary
Table 5), age remained significantly associated with
adherence, but current smoking and education did not.
Furthermore, history of diabetes became significantly
associated with adherence, but there was no association
with the additional variables. A nonpositive perception
of the study, however, was borderline significantly asso-
ciated with poorer adherence (0.12 [0.01–1.02],
P 5 .053).4. Discussion
Successful dementia preventionmay require adherence to
a variety of interventions, including medical consultations,
medication or supplement use, dietary changes, physical ac-
tivity, and cognitive training, but there are a few data so far
about adherence to such interventions in this context. In two
of the longest and largest multidomain trials completed to
date for the prevention of cognitive decline, the proportion
of subjects who adhered to at least 66% of individual inter-
vention components ranged from 25% to 93%, with higher
rates for less burdensome components. The proportion of in-
dividuals who were adherent to all their assigned
Table 2
Multivariate multilevel logistic regression analyses showing associations between baseline characteristics and adherence to individual components of the
FINGER intervention (adherence defined as completion of at least 66% of the intervention component)
Characteristics
Cardiovascular
consultations (N 5 562) Nutrition (N 5 555)
Physical activity
(N 5 560)
Cognitive training
(N 5 558)
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Sociodemographic variables
Age 0.98 (0.89–1.08) .673 0.99 (0.94–1.04) .681 0.95 (0.91–0.99) .027 0.93 (0.89–0.98) .009
Female (vs. male) 1.77 (0.65–4.80) .265 1.41 (0.89–2.24) .146 0.73 (0.47–1.12) .153 1.25 (0.77–2.04) .368
Education .187 .634 .340 .034
Low (ref) 1.00 1.00 1.00 1.00
Intermediate 2.54 (0.91–7.15) .077 1.26 (0.78–2.05) .339 1.37 (0.87–2.16) .173 1.95 (1.18–3.23) .009
High 1.76 (0.59–5.24) .310 1.11 (0.65–1.89) .712 1.02 (0.62–1.69) .933 1.42 (0.79–2.55) .237
Cognition, mood, physical status
MMSE ,28 (vs. 28) 1.36 (0.56–3.32) .500 1.21 (0.78–1.87) .388 0.66 (0.44–0.99) .046 1.35 (0.85–2.13) .200
TMT-A (per second increase) 0.98 (0.96–1.01) .148 0.99 (0.98–1.00) .083 0.99 (0.98–1.00) .246 0.99 (0.98–1.01) .316
Presence of depressive symptoms 1.36 (0.34–5.50) .664 0.55 (0.29–1.05) .072 0.32 (0.16–0.64) .001 0.89 (0.40–1.96) .768
SPPB ,10 0.70 (0.19–2.52) .585 0.69 (0.36–1.32) .263 0.70 (0.37–1.34) .282 0.48 (0.21–1.10) .081
Lifestyle variables
Smoking .480 .002 .050 .027
Never smoked (ref) 1.00 1.00 1.00 1.00
Former smoker 0.62 (0.24–1.61) .326 0.89 (0.55–1.45) .643 0.66 (0.42–1.03) .067 0.99 (0.59–1.65) .966
Current smoker 0.51 (0.14–1.87) .309 0.32 (0.16–0.61) .001 0.47 (0.23–0.96) .038 0.24 (0.09–0.70) .008
Alcohol within European
recommended weekly limit
2.89 (0.82–10.22) .100 0.84 (0.36–1.95) .687 1.26 (0.59–2.67) .551 1.06 (0.44–2.60) .890
Physical activity .175 .267 .023 .082
, 100 min/wk 1.00 1.00 1.00 1.00
 100 min/wk 1.92 (0.73–5.08) .186 1.42 (0.87–2.32) .162 1.90 (1.20–3.00) .006 1.86 (1.08–3.21) .026
Missing data 0.76 (0.25–2.29) .620 0.98 (0.50–1.91) .957 1.73 (0.87–3.41) .116 1.50 (0.65–3.44) .342
BMI .104 .022 .321 .537
18.5–24.9 (ref) 1.00 1.00 1.00 1.00
25–29.9 0.69 (0.24–1.93) .475 1.43 (0.87–2.34) .157 0.91 (0.57–1.48) .712 1.15 (0.66–1.99) .616
30 2.63 (0.62–11.17) .190 2.35 (1.28–4.30) .006 1.31 (0.76–2.26) .332 1.41 (0.77–2.59) .271
Cardiovascular variables
History of diabetes 0.44 (0.14–1.42) .170 0.66 (0.36–1.22) .185 0.49 (0.27–0.90) .022 0.79 (0.39–1.59) .511
History of high BP 1.50 (0.62–3.63) .363 0.95 (0.60–1.49) .812 0.99 (0.65–1.52) .981 1.56 (0.95–2.55) .077
History of high cholesterol 1.87 (0.77–4.53) .167 1.12 (0.71–1.75) .628 1.42 (0.94–2.14) .098 1.01 (0.63–1.62) .967
History of stroke — — 5.22 (1.13–24.05) .034 1.29 (0.51–3.27) .585 0.41 (0.11–1.56) .191
History of MI 0.58 (0.14–2.48) .467 0.77 (0.33–1.83) .559 0.91 (0.36–2.26) .834 0.78 (0.27–2.29) .652
Abbreviations: BMI, Body mass index; BP, blood pressure; CI, confidence interval; FINGER, Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment and Disability; MI, myocardial infarction; MMSE, Mini-Mental Status Examination; OR, odds ratio; SPPB, Short Physical Performance Battery;
TMT-A, Trail Making Test–part A.
NOTE. Low education 5 primary school certificate or lower; intermediate education 5 middle/vocational school; high education 5 high school diploma
(e.g., baccalaureate) or higher.
P values ,.05 are highlighted in bold.
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nition of adherence, and 39% to 51% using each trial’s pre-
specified definition, and decreased with increasing
intervention complexity and intensity. Adherence was also
influenced by participant characteristics, with depressive
symptoms and current smoking being the most consistent
predictors of poor adherence, but results varied across inter-
vention components and trials.
Long-term adherence rates were excellent for cardiovas-
cular monitoring and nutritional counseling in FINGER,
and very good for the dietary supplement in MAPT. These
were the least “active” components of the two trials’ inter-
ventions, but greater burden was not necessarily a major
barrier to adherence, because in FINGER, around half of
the participants completed at least 66% of the exercise ses-sions, and 74% of MAPT participants completed at least
75% of the multidomain sessions during the intensive inter-
vention phase during the first 2 months of the trial (data not
shown). Difficulties in accessing primary care in Finland
could also contribute the high adherence to the cardiovas-
cular consultations in FINGER. Furthermore, adherence
in FINGER was highest to individual visits (both cardio-
vascular consultations and nutritional counseling) where
the timing of the visit was scheduled together with the
participant (data not shown). It is unknown what level of
adherence is needed for a given intervention to have an ef-
fect on cognition. Thus, the cutoffs we used to define
adherence were somewhat arbitrary, and further work is
required to determine the impact of intervention adherence
on efficacy.
Table 3
Multivariate multilevel logistic regression analyses showing associations between baseline characteristics and adherence to individual MAPT interventions
(adherence defined as completion of at least 66% of the intervention component)
Characteristics
Multidomain intervention (N 5 692) Omega-3/placebo (N 5 647)
OR (95% CI) P OR (95% CI) P
Sociodemographic variables
Age 0.98 (0.94–1.02) .399 0.97 (0.92–1.01) .159
Female (vs. male) 1.24 (0.83–1.86) .293 0.63 (0.39–1.03) .066
Education .923 .035
Low (ref) 1 1
Intermediate 1.01 (0.62–1.64) .980 2.04 (1.15–3.61) .014
High 0.93 (0.56–1.53) .778 1.27 (0.73–2.21) .402
Cognition, mood, physical status
MMSE ,28 (vs. 28) 0.64 (0.44–0.95) .024 1.10 (0.69–1.76) .692
TMT-A (per second increase) 0.99 (0.98–1.00) .122 0.99 (0.98–1.00) .212
Presence of depressive symptoms 0.47 (0.30–0.72) .001 0.43 (0.26–0.70) .001
SPPB ,10 0.77 (0.50–1.18) .227 0.83 (0.50–1.36) .462
Lifestyle variables
Smoking .125 .328
Never smoked (ref) 1 1
Former smoker 1.12 (0.76–1.66) .567 1.11 (0.70–1.77) .645
Current smoker 0.44 (0.18–1.08) .073 0.53 (0.20–1.41) .206
Alcohol within recommended weekly
limit
0.74 (0.45–1.22) .237 1.03 (0.58–1.81) .931
100 min physical activity/wk 1.08 (0.69–1.71) .732 0.75 (0.44–1.30) .308
BMI .014 .763
18.5–24.9 (ref) 1 1
25–29.9 0.55 (0.37–0.83) .004 0.86 (0.54–1.36) .513
30 0.66 (0.39–1.13) .127 0.83 (0.44–1.56) .561
Cardiovascular variables
History of diabetes 0.73 (0.38–1.38) .327 0.96 (0.43–2.13) .922
History of high BP 0.69 (0.48–1.00) .047 0.82 (0.53–1.26) .371
History of high cholesterol 1.11 (0.77–1.59) .583 0.93 (0.61–1.42) .748
History of stroke 1.18 (0.51–2.75) .696 0.78 (0.31–1.99) .605
History of MI 1.80 (0.59–5.46) .299 0.79 (0.23–2.67) .706
Abbreviations: BMI, Body mass index; BP, blood pressure; CI, confidence interval; MAPT, Multidomain Alzheimer Preventive Trial; MI, myocardial infarc-
tion; MMSE, Mini-Mental Status Examination; OR, odds ratio; SPPB, Short Physical Performance Battery; TMT-A, Trail Making Test–part A.
NOTE. Low education 5 primary school certificate or lower; intermediate education 5 middle/vocational school; high education 5 high school diploma
(e.g., baccalaureate) or higher.
P values ,.05 are highlighted in bold.
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explained by several factors. First, the cognitive training was
computer-based and only 54% of participants reported pre-
vious computer experience at baseline. Indeed, this was a
strong predictor of adherence to both cognitive training
and the multidomain intervention as a whole, and not having
a computer was the main self-reported reason for not partici-
pating in the cognitive training (data not shown). Second,
this was the least supervised component of the FINGER
intervention, because participants were primarily asked to
complete the cognitive training independently. Older people
are not necessarily averse to cognitive training in itself,
because 64% of MAPT participants adhered to the multido-
main sessions, which included supervised pen- and paper-
based cognitive training exercises, and 59% of FINGER par-
ticipants adhered to group cognitive training sessions (data
not shown). Therefore, despite the logistical burden, future
trials should not underestimate the necessity of supervisedinterventions, particularly when using techniques or technol-
ogies with which older participants may not be familiar.
However, with increasing Internet skills in older populations
in recent years [25], computer-based interventions might
now be more feasible in this age group. Insight into the
acceptability of a preventive Internet intervention in older
European adults will be provided by the recently completed
Healthy Ageing Through Internet Counselling in the Elderly
trial [26]. Initial qualitative results suggest that human sup-
port may be crucial for the success of this kind of interven-
tion in older age groups [27].
Identifying factors associated with adherence can help to
improve implementation of prevention programs and under-
stand potential biases in research studies [9,28]. There are
few studies of predictors of adherence to multidomain
interventions in older populations [9,29,30], and none have
simultaneously investigated adherence to individual
components and multidomain interventions as a whole, or
Table 4
Multivariate multilevel logistic regression models showing associations between baseline characteristics and simultaneous adherence to all intervention
components in MAPT and FINGER (adherence defined as completion of at least 66% of the intervention component)
Characteristics
Simultaneous adherence to all
components of FINGER intervention
(N 5 558)
Simultaneous adherence to both
components of MAPT intervention
(N 5 647)
OR (95% CI) P OR (95% CI) P
Sociodemographic variables
Age 0.91 (0.86–0.97) .001 0.97 (0.93–1.02) .211
Female (vs. male) 1.08 (0.63–1.84) .789 0.94 (0.63–1.40) .754
Education .033 .543
Low (ref) 1.00 1.00
Intermediate 2.08 (1.20–3.63) .010 1.23 (0.76–2.00) .405
High 1.65 (0.86–3.14) .131 1.00 (0.62–1.63) .993
Cognition, mood, physical status
MMSE ,28 (vs. 28) 1.29 (0.78–2.13) .330 0.76 (0.52–1.11) .159
TMT-A (per second increase) 1.00 (0.98–1.01) .654 0.99 (0.98–1.00) .160
Presence of depressive symptoms 0.88 (0.37–2.08) .768 0.47 (0.30–0.73) .001
SPPB ,10 0.51 (0.20–1.31) .164 0.82 (0.53–1.27) .373
Lifestyle variables
Smoking .118 .100
Never smoked (ref) 1.00 1.00
Former smoker 0.82 (0.46–1.46) .498 1.00 (0.68–1.46) .986
Current smoker 0.32 (0.11–0.95) .039 0.37 (0.15–0.94) .036
Alcohol within recommended weekly limit 1.43 (0.52–3.96) .486 0.97 (0.60–1.55) .889
100 min physical activity/wk (vs. ,100 min)* 1.44 (0.79–2.60) .231 1.07 (0.68–1.67) .782
BMI .486 .435
18.5–24.9 (ref) 1.00 1.00
25–29.9 1.22 (0.66–2.24) .533 0.78 (0.53–1.15) .208
30 1.51 (0.77–2.95) .232 0.81 (0.48–1.37) .436
Cardiovascular variables
History of diabetes 0.54 (0.23–1.24) .145 0.55 (0.29–1.04) .065
History of high BP 1.59 (0.92–2.74) .097 0.85 (0.59–1.21) .363
History of high cholesterol 1.42 (0.84–2.40) .195 0.97 (0.68–1.38) .868
History of stroke 0.55 (0.14–2.20) .396 0.89 (0.39–2.04) .787
History of MI 0.74 (0.21–2.61) .636 0.78 (0.28–2.13) .623
Abbreviations: BMI, Body mass index; BP, blood pressure; CI, confidence interval; FINGER, Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment and Disability; MAPT, Multidomain Alzheimer Preventive Trial; MI, myocardial infarction; MMSE, Mini-Mental Status Examination; OR,
odds ratio; SPPB, Short Physical Performance Battery; TMT-A, Trail Making Test–part A.
NOTE. Low education 5 primary school certificate or lower; intermediate education 5 middle/vocational school; high education 5 high school diploma
(e.g., baccalaureate) or higher. Adherence to all components of the FINGER intervention means completing 66% of the cardiovascular, nutrition, physical
exercise, and cognitive training components. Adherence to both components of the MAPT intervention means attending 66% of the multidomain sessions
and taking 66% of the placebo or omega-3 supplement capsules.
P values ,.05 are highlighted in bold.
*For FINGER, the model also included a category for individuals with missing data for this variable (N 5 69; data not shown).
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across different trials. Results of previous analyses
have varied, probably because of, in particular, differences
in intervention strategies, study populations, and
methodologies.
Depressive symptoms were significantly associated with
poorer adherence to both intervention components in
MAPT, and with physical activity, and, to a lesser extent,
nutrition in FINGER. Some previous studies have also
observed an association between depression and decreased
adherence to physical exercise [31,32], and it is a well-
known predictor of medication/supplement nonadherence
[33,34].
Self-efficacy is one of the most important predictors of
adherence to lifestyle interventions, particularly physical ac-tivity, in older adults [28,31,35–38]. It was not measured in
either MAPT or FINGER, but in FINGER, participants’
initial perception of the study, which is the closest proxy,
was not significantly associated with adherence to physical
activity, although it was associated with adherence to
cognitive training and with simultaneous adherence to all
intervention components.
Cognition might also be expected to affect adherence.
However, only some [9,39,40], but not all [29,41],
previous studies have found an association. Likewise,
associations between cognition and adherence were
inconsistent in our analysis, and in particular appeared to
be dependent on the definition of adherence used.
Concerning health behaviors, current smoking is a well-
known predictor of poorer adherence to both lifestyle and
N. Coley et al. / Alzheimer’s & Dementia 15 (2019) 729-741738drug/supplements [28,33,42,43], and was one of the most
consistent predictors of (poor) adherence in our analyses.
As also expected [30,36,44], increased baseline physical
activity was associated with better adherence to the
FINGER physical activity intervention. It was also
associated with better adherence to the FINGER
cognitive training, supporting previous studies, which
have found physical activity to predict adherence to
various lifestyle interventions [29,45,46]. However, it was
not associated with any MAPT adherence indicators,
perhaps because of the self-reported nature of the physical
activity data and the cutoff used to distinguish between
physically active and inactive participants, which may not
have been optimal.
Sociodemographic factors are inconsistent predictors of
adherence to lifestyle interventions in the literature, and
this was reflected in our results: age, sex, and education
were not consistent strong predictors of adherence, particu-
larly in fully adjusted models, but females were significantly
more likely to adhere to the nutrition sessions in FINGER, as
in previous studies [9,30,42,46]. An intermediate (compared
with low) level of education was significantly associated
with poorer adherence in some analyses, but the secondary
FINGER analyses suggested that in fact this could be a
reflection of low income. The perceived expense of
maintaining a healthy lifestyle, particularly a healthy diet,
could conceivably influence the decision to make lifestyle
changes for some participants, notably those with low
income. Indeed, financial costs were identified as a
recurring barrier to the uptake and maintenance of various
healthy behaviors during midlife in a recent systematic
review [47].
The strengths of this study include the original nature of
the data, the large sample sizes, the use of multivariate an-
alyses adjusted for numerous factors (in contrast to some
previous studies [30,38,42]), including a core set of
variables that were common across two trials.
Furthermore, we used a (modified) intention to treat
definition of adherence [28], meaning that we did not arti-
ficially inflate estimates of adherence rates through our
handling of dropouts. However, our analysis also has
some limits, including its exploratory nature, the methodo-
logical differences between the two trials, and the fact that
not all relevant predictors of adherence, notably self-
efficacy, were assessed. Also, we only assessed baseline
predictors of adherence, but it may also be important to
consider variables measured at different time points,
notably for those relating to health status, which is likely
to change over time, particularly in older populations,
and which is likely to influence adherence. Our results
are also dependent on the definition of adherence, although
they remained relatively stable in sensitivity analyses using
alternative definitions. Furthermore, for some intervention
components, for example the nutrition components in
both trials, we simply measured study attendance, rather
than whether participants were actually making lifestylechanges. However, the two are likely to be strongly related
[48,49]. Also, we only studied a selected population of
individuals who had agreed to take part in a long-term
multidomain lifestyle intervention trial. Finally, we exam-
ined adherence for the entire follow-up period, because
we were interested in whether individuals adhered long
term to the interventions they were prescribed, and also,
intervention intensity over time differed between the two
trials, which would have made it challenging to perform
a comparable analysis. However, there may be certain pe-
riods during long-term lifestyle interventions for which
adherence may be more critical than others, and also pre-
dictors of adherence may change over time [28,36].
These issues require further study.5. Conclusion
Multidomain interventions may be burdensome and not
universally acceptable. Adherence to such interventions de-
pends on participant characteristics, as well as intervention
type, intensity, and method of delivery. Future trials should
consider ways to reduce participant burden and increase
adherence. The development of interventions based on
Internet or smartphone and the use of connected devices
could decrease the burden of multidomain interventions,
but they may not yet be universally acceptable in older pop-
ulations, thus potentially compromising uptake and adher-
ence in some individuals, and further enhancing
inequalities in access to prevention programs. Furthermore,
face-to-face contact appears to be particularly important in
older populations, both to facilitate intervention adherence
and stimulate social interactions, which may be a valuable
dementia prevention strategy [1]. A more personalized
approach to multidomain interventions could also be envis-
aged, inwhich participants could be offered interventions tar-
geting their own specific risk factors, and extra motivational
interventions could be included for individuals atmost risk of
nonadherence, notably smokers and those with depressive
symptoms. Finally, it may be helpful to emphasize, particu-
larly for those with low socioeconomic status, that lifestyle
changes can be made without incurring major expenses.Acknowledgments
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1. Systematic review: The literature was reviewed using
PubMed and the authors’ own files and reference
lists. There have been few studies of adherence to
multidomain interventions in older adults, particu-
larly not in the context of dementia prevention. Con-
clusions from previous studies are limited by
variations in adherence definitions and candidate
predictor variables, and, sometimes, unadjusted sta-
tistical analyses.
2. Interpretation: Adherence to multidomain interven-
tions depends on participant characteristics, as well
as intervention type, intensity, and method of deliv-
ery. Unsupervised interventions and use of new tech-
nologies may be challenging in older populations.
Current smoking and depressive symptoms were
consistent predictors of adherence, across both trials
and when using different definitions of adherence
and adjustment models.
3. Future directions: Future trials should consider ways
to reduce participant burden, while maintaining face-
to-face contacts and ensuring that technological tools
are suitable for older individuals. Extra motivational
interventions could be included for individuals at
most risk of nonadherence.
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